Semaglutide vs. Tirzepatide: What's the Difference?

Semaglutide and tirzepatide are both prescription medications used for chronic weight management in eligible patients. They are not interchangeable — selection depends on individual health factors.

Mechanism: Semaglutide is a GLP-1 receptor agonist. Tirzepatide activates both GIP and GLP-1 receptors. Both affect appetite and metabolism, but the dual action of tirzepatide is a distinguishing feature.

Administration: Both are typically self-injected weekly after provider training. Dosing schedules start low and increase over weeks.

Side effect profile: Both commonly cause GI symptoms during titration. Individual tolerance varies — one medication may be better tolerated than another for a given person.

Efficacy context: Clinical trials have reported weight loss with both medications, with trial designs and populations differing. Avoid assuming one is universally superior — your provider weighs evidence alongside your health history, insurance coverage, and tolerance.

Cost and access: Pricing and insurance coverage differ by medication and plan. NeuMed can discuss options during consultation and direct you to current pricing.

Next step: A medical weight loss consultation helps determine whether GLP-1 therapy is appropriate and which option fits your situation.